Marlborough medical device company Boston Scientific’s fourth generation Vercise Genus Deep Brain Stimulation System has received FDA approval, the company announced on Friday.
The portfolio, which is approved for conditional use in MRI environments, includes a family of Bluetooth-enabled, rechargeable and non-rechargeable, implantable pulse generators powering Cartesia Directional Leads, which are intended to provide symptom relief for Parkinson’s disease.
The Vercise Genus System treats Parkinson’s symptoms by delivering targeted electrical stimulation through the surgically-implanted leads in the brain, according to Boston Scientific.
FDA approval gives the greenlight to the system’s fourth generation, which originally launched in 2012. The system launched in Europe in September.
